Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer - A pilot study

Yuen Liang Lai, Hen Hong Chang, Ming Jer Huang, Kou Hwa Chang, Wen Hao Su, Hong Wen Chen, Chang Hung Chung, Wen Yu Wang, Li Hua Lin, Yu Jen Chen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

It has been reported that arsenic trioxide (As2O3) is an apoptosis inducer and radiation sensitizer for various cancer cell lines. In this study of breast cancer patients, we examined the combined effect of topical As2O3 and radiation therapy on fungating and/or skin-infiltrating lesions of breast cancer. The dermatological, gastrointestinal, hematological, renal and hepatic toxicities of the treatment were also monitored. As2O3 gel (0.05%) was applied to tumor lesions 1 h prior to delivery of each fraction, with the gel removed about 5 min before the irradiation. Superficial radiation was delivered using an electron beam from a linear accelerator. Every week, the tumor lesions were photographed to evaluate effectiveness, and blood was sampled to monitor changes in hemogram and biochemical profile. Seven breast cancer patients with cutaneous metastasis were enrolled in this study. In terms of tumor, the rates for complete, partial response and stable disease were 42.9 (three of seven), 42,9 (three of seven) and 14.3% (one of seven), respectively. The skin pain, assessed by a visual analog scale, and secretion from all of the seven superficial and fungating wounds decreased markedly after treatment Significant bone marrow suppression or granulocytosis was not noted. Further, changes in renal and hepatic function were also not significant It seems reasonable to conclude that As2O3 may be an effective and safe radiosensitizer for palliative radiotherapy for skin-infiltrating lesions of breast cancer.

Original languageEnglish
Pages (from-to)825-828
Number of pages4
JournalAnti-Cancer Drugs
Volume14
Issue number10
Publication statusPublished - Nov 2003

Fingerprint

Radiotherapy
Breast Neoplasms
Skin
Neoplasms
Gels
Radiation-Sensitizing Agents
Kidney
Particle Accelerators
Liver
Visual Analog Scale
Bone Marrow
arsenic trioxide
Electrons
Radiation
Apoptosis
Neoplasm Metastasis
Pain
Cell Line
Wounds and Injuries
Therapeutics

Keywords

  • Arsenic trioxide
  • Cutaneous metastasis
  • Radiotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Lai, Y. L., Chang, H. H., Huang, M. J., Chang, K. H., Su, W. H., Chen, H. W., ... Chen, Y. J. (2003). Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer - A pilot study. Anti-Cancer Drugs, 14(10), 825-828.

Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer - A pilot study. / Lai, Yuen Liang; Chang, Hen Hong; Huang, Ming Jer; Chang, Kou Hwa; Su, Wen Hao; Chen, Hong Wen; Chung, Chang Hung; Wang, Wen Yu; Lin, Li Hua; Chen, Yu Jen.

In: Anti-Cancer Drugs, Vol. 14, No. 10, 11.2003, p. 825-828.

Research output: Contribution to journalArticle

Lai, YL, Chang, HH, Huang, MJ, Chang, KH, Su, WH, Chen, HW, Chung, CH, Wang, WY, Lin, LH & Chen, YJ 2003, 'Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer - A pilot study', Anti-Cancer Drugs, vol. 14, no. 10, pp. 825-828.
Lai, Yuen Liang ; Chang, Hen Hong ; Huang, Ming Jer ; Chang, Kou Hwa ; Su, Wen Hao ; Chen, Hong Wen ; Chung, Chang Hung ; Wang, Wen Yu ; Lin, Li Hua ; Chen, Yu Jen. / Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer - A pilot study. In: Anti-Cancer Drugs. 2003 ; Vol. 14, No. 10. pp. 825-828.
@article{c1e676654a8f4313aefc0598fdc27420,
title = "Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer - A pilot study",
abstract = "It has been reported that arsenic trioxide (As2O3) is an apoptosis inducer and radiation sensitizer for various cancer cell lines. In this study of breast cancer patients, we examined the combined effect of topical As2O3 and radiation therapy on fungating and/or skin-infiltrating lesions of breast cancer. The dermatological, gastrointestinal, hematological, renal and hepatic toxicities of the treatment were also monitored. As2O3 gel (0.05{\%}) was applied to tumor lesions 1 h prior to delivery of each fraction, with the gel removed about 5 min before the irradiation. Superficial radiation was delivered using an electron beam from a linear accelerator. Every week, the tumor lesions were photographed to evaluate effectiveness, and blood was sampled to monitor changes in hemogram and biochemical profile. Seven breast cancer patients with cutaneous metastasis were enrolled in this study. In terms of tumor, the rates for complete, partial response and stable disease were 42.9 (three of seven), 42,9 (three of seven) and 14.3{\%} (one of seven), respectively. The skin pain, assessed by a visual analog scale, and secretion from all of the seven superficial and fungating wounds decreased markedly after treatment Significant bone marrow suppression or granulocytosis was not noted. Further, changes in renal and hepatic function were also not significant It seems reasonable to conclude that As2O3 may be an effective and safe radiosensitizer for palliative radiotherapy for skin-infiltrating lesions of breast cancer.",
keywords = "Arsenic trioxide, Cutaneous metastasis, Radiotherapy",
author = "Lai, {Yuen Liang} and Chang, {Hen Hong} and Huang, {Ming Jer} and Chang, {Kou Hwa} and Su, {Wen Hao} and Chen, {Hong Wen} and Chung, {Chang Hung} and Wang, {Wen Yu} and Lin, {Li Hua} and Chen, {Yu Jen}",
year = "2003",
month = "11",
language = "English",
volume = "14",
pages = "825--828",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer - A pilot study

AU - Lai, Yuen Liang

AU - Chang, Hen Hong

AU - Huang, Ming Jer

AU - Chang, Kou Hwa

AU - Su, Wen Hao

AU - Chen, Hong Wen

AU - Chung, Chang Hung

AU - Wang, Wen Yu

AU - Lin, Li Hua

AU - Chen, Yu Jen

PY - 2003/11

Y1 - 2003/11

N2 - It has been reported that arsenic trioxide (As2O3) is an apoptosis inducer and radiation sensitizer for various cancer cell lines. In this study of breast cancer patients, we examined the combined effect of topical As2O3 and radiation therapy on fungating and/or skin-infiltrating lesions of breast cancer. The dermatological, gastrointestinal, hematological, renal and hepatic toxicities of the treatment were also monitored. As2O3 gel (0.05%) was applied to tumor lesions 1 h prior to delivery of each fraction, with the gel removed about 5 min before the irradiation. Superficial radiation was delivered using an electron beam from a linear accelerator. Every week, the tumor lesions were photographed to evaluate effectiveness, and blood was sampled to monitor changes in hemogram and biochemical profile. Seven breast cancer patients with cutaneous metastasis were enrolled in this study. In terms of tumor, the rates for complete, partial response and stable disease were 42.9 (three of seven), 42,9 (three of seven) and 14.3% (one of seven), respectively. The skin pain, assessed by a visual analog scale, and secretion from all of the seven superficial and fungating wounds decreased markedly after treatment Significant bone marrow suppression or granulocytosis was not noted. Further, changes in renal and hepatic function were also not significant It seems reasonable to conclude that As2O3 may be an effective and safe radiosensitizer for palliative radiotherapy for skin-infiltrating lesions of breast cancer.

AB - It has been reported that arsenic trioxide (As2O3) is an apoptosis inducer and radiation sensitizer for various cancer cell lines. In this study of breast cancer patients, we examined the combined effect of topical As2O3 and radiation therapy on fungating and/or skin-infiltrating lesions of breast cancer. The dermatological, gastrointestinal, hematological, renal and hepatic toxicities of the treatment were also monitored. As2O3 gel (0.05%) was applied to tumor lesions 1 h prior to delivery of each fraction, with the gel removed about 5 min before the irradiation. Superficial radiation was delivered using an electron beam from a linear accelerator. Every week, the tumor lesions were photographed to evaluate effectiveness, and blood was sampled to monitor changes in hemogram and biochemical profile. Seven breast cancer patients with cutaneous metastasis were enrolled in this study. In terms of tumor, the rates for complete, partial response and stable disease were 42.9 (three of seven), 42,9 (three of seven) and 14.3% (one of seven), respectively. The skin pain, assessed by a visual analog scale, and secretion from all of the seven superficial and fungating wounds decreased markedly after treatment Significant bone marrow suppression or granulocytosis was not noted. Further, changes in renal and hepatic function were also not significant It seems reasonable to conclude that As2O3 may be an effective and safe radiosensitizer for palliative radiotherapy for skin-infiltrating lesions of breast cancer.

KW - Arsenic trioxide

KW - Cutaneous metastasis

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=12144291654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144291654&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 825

EP - 828

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 10

ER -